Ambelvist FDA Approval Expands Low-Dose MRI Contrast Agent Options

Ambelvist is now the lowest-dose macrocyclic gadolinium-based contrast agent approved in the US, offering a new option for contrast-enhanced MRI in adults and children. 

Identifying lesions, which are areas of disease or damage, in the brain, spine and other parts of the body can help clinicians detect conditions such as cancer, inflammation and neurological disease. Because these lesions are often assessed through magnetic resonance imaging (MRI), scan clarity can play an important role in diagnosis, monitoring and treatment planning.

The FDA has approved Ambelvist (gadoquatrane), Bayer’s new low-dose MRI contrast agent, to help detect and visualize lesions with abnormal vascularity. These are diseased or damaged areas with an irregular network of blood vessels, which contrast agents can help make easier to see on scans.

Ambelvist is approved for adults and children, including full-term newborns. The approval covers the central nervous system (CNS), which includes the brain and spine, as well as non-CNS body regions such as the chest, abdomen, pelvis and musculoskeletal system.

MRI uses magnetic fields and radio waves to create detailed images of organs and tissues. In some cases, physicians use a gadolinium-based contrast agent (GBCA), an injectable substance given before a scan, to improve image clarity, track disease progression or evaluate how a patient is responding to treatment.

Ambelvist is now the lowest-dose macrocyclic GBCA approved in the US. Macrocyclic refers to a stable, ring-like chemical structure that holds gadolinium. Ambelvist also has a tetrameric structure, meaning four gadolinium-containing units are linked together in a single molecule. This design gives the agent high relaxivity, which helps strengthen the MRI signal while using less gadolinium.

Xtalks Insights

Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.

First Name *

Email *

By clicking this checkbox, I agree to receive Xtalks communications and understand that I may unsubscribe at any time. Please review the Xtalks privacy policy here.

Protected by reCAPTCHA.

Continue

What topics would you like to hear more about?

Select all that apply.

Science and Discovery Clinical Development Regulatory Safety and Quality Manufacturing and Supply Chain Commercial and Market Access Data AI and Digital Therapeutic Areas

Progress

1 2 3

Next Step

Want to get even more specific?

Help us narrow down the sub-topics that you're most interested in.

Progress

1 2 3

Save Preferences

Thank you!

For webinars, videos, podcasts and more from Xtalks, join our community today.

BECOME A FREE MEMBER

Progress

1 2 3

A 2024 Investigative Radiology study found that gadoquatrane produced similar MRI image brightening to gadobutrol, an established macrocyclic MRI contrast agent.

The recommended dose of Ambelvist is 0.01 mmol/kg of actual body weight. Bayer said this dose delivers 60% less gadolinium than many common macrocyclic agents dosed at 0.1 mmol/kg and 20% less than gadopiclenol, another lower-dose agent.

Gadopiclenol, sold as Vueway, was first approved by the FDA in 2022, and its use was expanded in February 2026 to include neonates and infants. 

Ambelvist’s lower-dose profile could be especially relevant for patients who need repeated scans, such as those with multiple sclerosis or certain cancers, to track disease progression or treatment response.

The approval was supported by Bayer’s global Phase III QUANTI clinical studies, which showed that combining pre-contrast and post-contrast scans with Ambelvist improved lesion visualization compared with scans taken without a contrast agent.

The trials also showed that Ambelvist, at its 0.01 mmol/kg dose, produced visualization scores and lesion counts similar to those of the tested macrocyclic agents used at higher gadolinium content. This means radiologists identified a similar number of lesions despite the lower exposure to gadolinium.

Ambelvist carries a boxed warning related to improper intrathecal use and nephrogenic systemic fibrosis, a rare but severe condition involving scarring of the skin and internal organs, with risk highest in patients with serious kidney problems.